<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03464903</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00091570</org_study_id>
    <secondary_id>8007</secondary_id>
    <nct_id>NCT03464903</nct_id>
  </id_info>
  <brief_title>Study of ALS Reversals 2: Genetic Analyses</brief_title>
  <acronym>StAR2</acronym>
  <official_title>ALS Reversals: Genetic Analyses (St.A.R. Protocol 2) RDCRN CReATe Protocol #8007</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium (funded by NIH/NCATS/NINDS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to try to understand why reversals of amyotrophic lateral
      sclerosis (ALS) and primary muscular atrophy (PMA) take place. The study will enroll patients
      with ALS or PMA reversals to give saliva samples in order to determine if the ALS or PMA
      reversal is because of certain changes in the genetic code.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amyotrophic Lateral Sclerosis (ALS) is a devastating motor neuron disease that typically
      causes rapidly progressive muscle weakness, disability and premature death. In spite of a
      large number of attempted ALS trials, there are no significant disease-modifying therapies
      for this condition to-date.

      There exists a small group of patients who meet diagnostic criteria for ALS or progressive
      muscular atrophy (PMA), progress for a period of time, and then significantly improve. Some
      of these &quot;ALS reversals&quot; even make a complete recovery back to normal neurological function.
      The investigator has independently verified 34 of these cases so far through review of
      medical records and peer-reviewed literature. These patients are different in their
      demographics and disease characteristics as compared to patients with more typically
      progressive ALS. One possible explanation for these cases is that these patients are
      genetically different than most patients with ALS and that these differences confer a form of
      disease &quot;resistance&quot;. Study of these selected reversal patients may yield valuable clues to
      endogenous mechanisms of ALS resistance. The concept of genetic conferred ability to resist a
      disease is not novel. A group of patients who could unexpectedly &quot;control&quot; HIV due to a
      mutant allele has led to an improved understanding of HIV pathophysiology and a new treatment

      This is a pilot case-control study attempting to discover genetic correlates to ALS
      reversals. The investigator will collect demographics, disease characteristics, pedigree
      information and saliva samples from ALS reversals. Whole genome DNA will be extracted and
      sequenced from these saliva samples. The genomes of ALS reversals will then be compared with
      whole genome sequencing previously completed from a biorepository of de-identified samples of
      more typically progressive patients with ALS. The study will not save any saliva samples
      collected as a part of this new protocol for future research.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>genetic comparison</measure>
    <time_frame>1 day</time_frame>
    <description>comparison of genes of participants with ALS reversals to genes of more typically progressive patients with ALS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>factors associated with genes</measure>
    <time_frame>1 day</time_frame>
    <description>further genetic analysis for any interaction of demographics, rate of disease progression, or disease characteristics</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Progressive Muscular Atrophy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be enrolled by invitation only. Potential participants will have had a
        previously verified diagnosis of ALS or PMA and a verified sustained and robust reversal of
        disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Prior participation in Documentation of Known ALS Reversals (Duke IRB Pro00076395)

          2. Confirmation of ALS or PMA (primary muscular atrophy) diagnosis through medical record
             review (previously documented in Documentation of Known ALS Reversals protocol)

          3. Sustained, robust improvement on at least one objective ALS outcomes measure (ex.
             ALSFRS-R, FVC, strength testing, EMG) (previously documented in Documentation of Known
             ALS Reversals protocol)

          4. Able to understand English

        Exclusion Criteria:

          1. History of cognitive impairment severe enough to preclude informed consent, reported
             by patient on direct questioning or as suspected by research personnel from
             Documentation of Known ALS Reversals (Duke IRB Pro00076395) study data

          2. Prior participation in the Phenotype Genotype and Biomarkers in ALS and Related
             Disorders (RDCRN #8001) protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard S Bedlack, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke ALS Clinic / DUSOM Dept of Neurology / DUHS</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.alsreversals.com</url>
    <description>public website advertising the Study of ALS Reversals Program (St.A.R.) and the Replication of ALS Reversals (R.O.A.R.) Program</description>
  </link>
  <link>
    <url>http://www.alsuntangled.com</url>
    <description>public website with reviews of alternative and off-label treatments with the goal of helping people with ALS make more informed decisions about them</description>
  </link>
  <reference>
    <citation>Ozdinler PH, Silverman RB. Treatment of amyotrophic lateral sclerosis: lessons learned from many failures. ACS Med Chem Lett. 2014 Oct 8;5(11):1179-81. doi: 10.1021/ml500404b. eCollection 2014 Nov 13.</citation>
    <PMID>25408825</PMID>
  </reference>
  <reference>
    <citation>http://www.wsj.com/articles/the-mystery-of-als-patients-who-see-improvement-1465845332</citation>
  </reference>
  <reference>
    <citation>ALSUntangled Group. ALSUntangled No. 12: Dean Kraft, Energy Healer. Amyotroph Lateral Scler. 2011 Sep;12(5):389-91. doi: 10.3109/17482968.2011.609309.</citation>
    <PMID>21981685</PMID>
  </reference>
  <reference>
    <citation>Harrison D and Bedlack R (unpublished data).</citation>
  </reference>
  <reference>
    <citation>Bedlack RS, Vaughan T, Wicks P, Heywood J, Sinani E, Selsov R, Macklin EA, Schoenfeld D, Cudkowicz M, Sherman A. How common are ALS plateaus and reversals? Neurology. 2016 Mar 1;86(9):808-12. doi: 10.1212/WNL.0000000000002251. Epub 2015 Dec 9.</citation>
    <PMID>26658909</PMID>
  </reference>
  <reference>
    <citation>Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996 Aug 22;382(6593):722-5.</citation>
    <PMID>8751444</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2018</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>amyotrophic lateral sclerosis</keyword>
  <keyword>progressive muscular atrophy</keyword>
  <keyword>motor neuron disease</keyword>
  <keyword>ALS reversals</keyword>
  <keyword>whole genome sequencing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information obtained from this analysis (genotypic data), as well as information about disease signs and symptoms (phenotypic data), will be entered into one or more scientific repositories maintained by organizations such as the New York Genome Center (NYGC) and the Federal Government. One such repository is the Database of Genotypes and Phenotypes (dbGaP), a data repository at the NIH. All data and information will be submitted via a secure transmission process to a high security network within NIH.
While the information and data resulting from this study may be presented at scientific meetings or published in a scientific journal, your name or other personal information will not be revealed.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

